コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 enza B, two respiratory syncytial virus, one parainfluenza).
2 ommon viral infections such as influenza and parainfluenza.
3 onse to a cluster of hospital-acquired human parainfluenza 3 virus (HPIV3) infections at a children's
4 nation respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal
8 -derived peptide sequence that inhibits both parainfluenza and Nipah viruses, to investigate the infl
9 Besides influenza A and RSV, influenza B, parainfluenza and norovirus may also contribute substant
12 95% confidence interval [CI], 1.02-4.69) and parainfluenza-ARI (AOR, 1.86; 95% CI, 1.15-3.01), when c
14 ate an etiologic role, whereas detections of parainfluenza, coronaviruses, rhinovirus, and adenovirus
15 luenza B, respiratory syncytial virus (RSV), parainfluenza, enterovirus, rotavirus, norovirus, Campyl
17 quely broad spectrum antiviral activity of a parainfluenza F-derived peptide sequence that inhibits b
24 monia was diagnosed in 10 (5 influenza and 5 parainfluenza) patients, and concurrent bacterial pneumo
25 gle-lung 25, double-lung 14) of influenza or parainfluenza respiratory viral infection were identifie
27 ically important viruses, such as influenza, parainfluenza, respiratory syncytial virus (RSV) and Ebo
28 nd early viral exposure to 3 common viruses (parainfluenza, respiratory syncytial virus, and picornav
29 itis virus, measles, mumps, metapneumovirus, parainfluenza, rotavirus, respiratory syncytial virus, a
33 In this study the solution dynamics of human parainfluenza type 3 hemagglutinin-neuraminidase (HN) ha
34 ubjects into respiratory syncytial virus and parainfluenza type 3 vaccine trials when subjects were s
37 Neu5Ac2en derivatives that target the human parainfluenza type-1 hemagglutinin-neuraminidase protein
39 vaccines against viruses such as influenza, parainfluenza types 1-3, measles, dengue, and respirator
40 ke (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as
41 canine adenovirus type 2 (CAV-2), and canine parainfluenza virus (CPIV), respiratory disease was ende
42 V-respiratory syncytial virus (RSV) or human parainfluenza virus (HPIV) coinfections had wheezing tha
44 presence of the second binding site on human parainfluenza virus (hPIV) type 1, 2, and 3 and Sendai v
45 es, Respiratory Syncytial Virus (RSV), Human Parainfluenza Virus (HPIV), and Human Metapneumovirus (h
46 (23), human herpesvirus (HHV)-6B (10), human parainfluenza virus (HPIV)-2 (3), HPIV-3 (1), and human
47 for RSV (n = 35), 2.6 x 10(6) copies/mL; for parainfluenza virus (n = 35), 4.9 x 10(7) copies/mL; for
48 rs mutations in the P/V gene from the canine parainfluenza virus (P/V-CPI(-)) is a potent inducer of
55 ually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3.
56 mens), followed by human rhinovirus (17.8%); parainfluenza virus (PIV) types 1-4 (7.5%); enterovirus
57 sting for respiratory syncytial virus (RSV), parainfluenza virus (PIV), and influenza A and B, and by
58 us (HRV), respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza virus (InfV), metap
59 (HN, residues 37 to 56) of the paramyxovirus parainfluenza virus (PIV5), a region of the HN stalk tha
60 naturally occurring SV5 variant Wake Forest parainfluenza virus (WF-PIV) activates the synthesis of
61 detects influenza A virus (Flu-A) and Flu-B, parainfluenza virus 1 (PIV-1), PIV-2, and PIV-3, and res
62 l virus (RSV), human metapneumovirus (HMPV), parainfluenza virus 1 to 3 (PIV1, PIV2, and PIV3), and a
63 hese are encoded by mumps virus (MuV), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5
64 Simian virus 5 (SV5) targets STAT1, human parainfluenza virus 2 targets STAT2, and mumps virus tar
65 ith respiratory syncytial virus (RSV), human parainfluenza virus 3 (HPIV-3), and influenza virus on t
67 titatively influence fusion promotion, human parainfluenza virus 3 (HPIV3) variants with alterations
68 yxoviruses, such as Nipah virus (NiV), human parainfluenza virus 3 (HPIV3), measles virus (MeV), mump
71 c fibrosis patients; however, its use during parainfluenza virus 3 (PIV3) infection has not been eval
74 eaved ectodomain of the paramyxovirus, human parainfluenza virus 3 fusion (F) protein, a member of th
79 cell lines with Sendai virus (SeV) or human parainfluenza virus 3, two prototypic paramyxoviruses, c
82 rus [EV], 118; bocavirus, 8; coronavirus, 7; parainfluenza virus 4, 4; Mycoplasma pneumoniae, 1).
83 hat Cav-1 colocalizes with the paramyxovirus parainfluenza virus 5 (PIV-5) nucleocapsid (NP), matrix
86 Proline substitution in this region of HN of parainfluenza virus 5 (PIV5) and Newcastle disease virus
87 In this work, we generated a recombinant parainfluenza virus 5 (PIV5) containing NP from H5N1 (A/
89 igh similarity to the structure of prefusion parainfluenza virus 5 (PIV5) F, with the main structural
90 Because only the prefusion structure of the parainfluenza virus 5 (PIV5) F-trimer is available, to s
91 MR spectroscopy, we show that the TMD of the parainfluenza virus 5 (PIV5) fusion protein adopts lipid
100 To investigate the role of NP protein in parainfluenza virus 5 (PIV5) particle formation, NP prot
102 serendipitously identified a viral mRNA from parainfluenza virus 5 (PIV5) that activates IFN expressi
104 quence variation of 16 different isolates of parainfluenza virus 5 (PIV5) that were isolated from a n
105 unable to be recognized by measles virus and parainfluenza virus 5 (PIV5) V proteins were tested in s
107 he threonine residue at position 286 of P of parainfluenza virus 5 (PIV5) was found phosphorylated.
108 The V proteins of measles virus (MV) and parainfluenza virus 5 (PIV5) were introduced into HFLC u
109 rotein (prefusion form) of the paramyxovirus parainfluenza virus 5 (PIV5) WR isolate was determined.
111 Similar results were also observed with parainfluenza virus 5 (PIV5), a paramyxovirus, when neut
116 V), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5 (PIV5), all members of the genus R
118 that a porcine isolate of the paramyxovirus parainfluenza virus 5 (PIV5), known as SER, requires a l
127 on (F) protein from the paramyxovirus simian parainfluenza virus 5 (SV5) resulted in mutant F protein
128 NASEK was dispensable for viruses, including parainfluenza virus 5 and Coxsackie B virus, that enter
129 ructed chimeras containing the ectodomain of parainfluenza virus 5 F (PIV5 F) and either the MPER, th
130 Here we report the crystal structure of the parainfluenza virus 5 F protein in its prefusion conform
131 ess the functional role of the paramyxovirus parainfluenza virus 5 F protein TM domain, alanine scann
133 , we show that the FP from the paramyxovirus parainfluenza virus 5 fusogenic protein, F, forms an N-t
134 ng globular head domain of the paramyxovirus parainfluenza virus 5 HN protein is entirely dispensable
135 usion activation, F activation involving the parainfluenza virus 5 HN stalk domain, and properties of
139 this study, we show that vaccination with a parainfluenza virus 5 recombinant vaccine candidate expr
140 ed "stalk exposure model" first proposed for parainfluenza virus 5 to other paramyxoviruses and propo
144 recently published prefusogenic structure of parainfluenza virus 5/SV5 F places CBF(2) in direct cont
146 d five in which the PLx-RVP failed to detect parainfluenza virus and one in which the detection of in
148 sociation with age; especially rhinovirus or parainfluenza virus detection showed positive associatio
157 to pneumonitis and/or mortality of treating parainfluenza virus infections with available (ribavirin
160 mouse model in which infection with a mouse parainfluenza virus known as Sendai virus (SeV) leads to
161 significance of membrane fusion activity in parainfluenza virus replication and pathogenesis in vivo
164 Human epithelial cells infected with the parainfluenza virus simian virus 5 (SV5) show minimal ac
165 aring the sequence of MV F with those of the parainfluenza virus SV5 and Newcastle disease virus (NDV
167 eviously described heterotypic peptides from parainfluenza virus that potently inhibit Nipah virus in
168 e protein or whole virus digests enables the parainfluenza virus to be identified and typed and for i
169 ontact transmission, the predominant mode of parainfluenza virus transmission, was modeled accurately
170 n to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second re
179 respiratory syncytial virus (RSV) and human parainfluenza virus type 1 (HPIV1) to HPIV4 infect virtu
180 onkeys from challenge with the related human parainfluenza virus type 1 (hPIV1), and SV has advanced
181 valuation of an attenuated recombinant human parainfluenza virus type 1 (rHPIV1) expressing the membr
185 live virus vaccine, we have used the murine parainfluenza virus type 1 (Sendai virus [SV]) as a xeno
186 Hamsters immunized with a recombinant human parainfluenza virus type 1 expressing the fusion F prote
188 secreted from A549 cells infected with Human parainfluenza virus type 2 (HPIV-2) but not from cells i
191 t for association with V proteins from human parainfluenza virus type 2, parainfluenza virus type 5,
195 ur previous observation on the role of human parainfluenza virus type 3 (HPIV 3) C protein in the tra
199 valent live attenuated vaccine against human parainfluenza virus type 3 (HPIV3) and respiratory syncy
200 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric r
201 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major viral agent
202 SV), human metapneumovirus (hMPV), and human parainfluenza virus type 3 (hPIV3) are responsible for t
203 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and sec
204 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are two major causes
206 genes, of a gene cassette encoding the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami
207 t also the receptor interaction of the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami
208 plementation to follow the dynamics of human parainfluenza virus type 3 (HPIV3) HN/F pairs in living
210 onnected to the stalk region of either human parainfluenza virus type 3 (HPIV3) or Nipah virus recept
211 against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to expre
212 rt here that for three paramyxoviruses-human parainfluenza virus type 3 (HPIV3), a major cause of low
214 common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector
215 encephalomyocarditis virus (EMCV) and human parainfluenza virus type 3 (HPIV3), induced down-regulat
216 ing the childhood respiratory pathogen human parainfluenza virus type 3 (HPIV3), possess an envelope
222 In this study, a chimeric bovine/human (b/h) parainfluenza virus type 3 (PIV3) expressing the human P
226 r the ability to inhibit the growth of human parainfluenza virus type 3 (PIV3), a nonsegmented negati
228 A live attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) was developed prev
231 tial innate antiviral response against human parainfluenza virus type 3 and respiratory syncytial vir
232 s virus of the Arenaviridae family and human parainfluenza virus type 3 of the Paramyxoviridae family
234 yncytial virus, human metapneumovirus, human parainfluenza virus type 3, and measles virus, and highl
235 uses, including the childhood pathogen human parainfluenza virus type 3, enter host cells by fusion o
236 explores the binding and entry into cells of parainfluenza virus type 3, focusing on how the receptor
237 minidase abolished infection of HAE by human parainfluenza virus type 3, this treatment did not signi
238 vaccine for respiratory syncytial virus and parainfluenza virus type 3, two major causes of severe r
239 viruses, including the human pathogen human parainfluenza virus type 3, yet these compounds by thems
240 protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that express
242 ction of interferon (IFN) alpha/beta against parainfluenza virus type 5 (PIV5), selectively inhibitin
243 teins from human parainfluenza virus type 2, parainfluenza virus type 5, measles virus, mumps virus,
245 luding influenza virus A, influenza virus B, parainfluenza virus types 1 and 3, respiratory syncytial
247 virus (RSV), influenza virus type A (FluA), parainfluenza virus types 1, 2, and 3 (PIV1, PIV2, and P
249 iruses, including influenza A and B viruses, parainfluenza virus types 1-3, respiratory syncytial vir
250 act of respiratory syncytial virus (RSV) and parainfluenza virus URIs on the frequency of AOM caused
253 infected cells (Wake Forest strain of Canine parainfluenza virus) induced IL-8 secretion by a mechani
254 pproach is further demonstrated here for the parainfluenza virus, a virus which can be life threateni
255 tory syncytial virus, human metapneumovirus, parainfluenza virus, and influenza virus) by reverse-tra
256 ents with respiratory syncytial virus (RSV), parainfluenza virus, influenza virus, metapneumovirus (M
257 roviruses, influenza virus, metapneumovirus, parainfluenza virus, rhinovirus, and respiratory syncyti
258 so showed that extraction will be needed for parainfluenza virus, which was only identified correctly
259 tudies we tested the role of CD8+ T cells in parainfluenza virus-induced hyperreactivity and M2R dysf
261 t for lower-respiratory-tract infection with parainfluenza virus; it stabilized during the months aft
262 he hemagglutinin-neuraminidase (HN) of human parainfluenza viruses (hPIV) in vitro and protected mice
265 glutinin-neuraminidase (HN) protein of human parainfluenza viruses (hPIVs) both binds (H) and cleaves
270 ed negative for respiratory syncytial virus, parainfluenza viruses (types 1-3), influenza A and B vir
272 virus, influenza A virus, influenza B virus, parainfluenza viruses 1 to 3, and respiratory syncytial
273 nfluenza A virus H1-2009, influenza B virus, parainfluenza viruses 1 to 4, respiratory syncytial viru
274 syncytial virus; influenza A and B viruses; parainfluenza viruses 1, 2, 3, and 4; human metapneumovi
275 an respiratory syncytial virus (HRSV); human parainfluenza viruses 1, 2, and 3 (HPIV1, -2, and -3, re
277 picornaviruses, coronaviruses 229E and OC43, parainfluenza viruses 1-3, influenza viruses AH1, AH3, a
278 in reaction for respiratory syncytial virus, parainfluenza viruses 1-4, influenza A and B, human meta
279 lture (metapneumovirus, coronaviruses [CoV], parainfluenza viruses 4a and 4b, and rhinoviruses) and t
284 (RSV), adenoviruses, influenza viruses, and parainfluenza viruses by use of nested polymerase chain
287 Our results illustrate how the particles of parainfluenza viruses efficiently accommodate cargoes of
291 ew evidence regarding strategies employed by parainfluenza viruses to effectively circumvent respirat
292 on of 274 of 279 influenza viruses, 33 of 38 parainfluenza viruses, 35 of 51 adenoviruses, and 52 of
293 etapneumovirus, respiratory syncytial virus, parainfluenza viruses, and Haemophilus influenzae being
294 causes of lower respiratory disease like the parainfluenza viruses, as well as agents of lethal encep
295 , which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and huma
296 ruses, including measles virus, mumps virus, parainfluenza viruses, respiratory syncytial virus, huma
300 y in all studied age groups; influenza B and parainfluenza were additionally associated in those aged
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。